We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Oral Bacteria May Diagnose Pancreatic Cancer

By LabMedica International staff writers
Posted on 04 Jun 2014
Image: The anaerobic bacteria Leptotrichia species, Gram-stain from blood culture (Photo courtesy of Mike Dyall-Smith).
Image: The anaerobic bacteria Leptotrichia species, Gram-stain from blood culture (Photo courtesy of Mike Dyall-Smith).
Patients with pancreatic cancer have a different and distinct profile of specific bacteria in their saliva compared to healthy controls and even patients with other cancers or pancreatic diseases.

Patients diagnosed in the early stages of pancreatic cancer have a 5-year survival rate of 21.5%, but unfortunately symptoms do not appear until after the cancer has become untreatable in the vast majority of cases.

Scientists from San Diego State University (CA, USA) compared the diversity of saliva bacteria across 131 patients, 63 females and 68 males, being treated at the University of California, San Diego (UCSD) Moores Cancer Center (La Jolla, CA, USA). Of these patients, 14 had been diagnosed with pancreatic cancer, 13 with pancreatic disease, 22 with other forms of cancer, and 10 were disease free.

The results of the study found that patients diagnosed with pancreatic cancer had higher levels of two particular oral bacteria, Leptotrichia and Campylobacter, when compared to any other healthy or diseased state including noncancerous pancreatic disease. Those with pancreatic cancer also had lower levels of Streptococcus, Treponema, and Veillonella. These findings could form the basis for a test to diagnose the pancreatic cancer in its early stages.

Pedro Torres, BS, the coauthor of the study with Scott T. Kelley, PhD, said, “Our studies suggest that ratios of particular types of bacteria found in saliva may be indicative of pancreatic cancer. The results also suggest the presence of a consistently distinct microbial profile for pancreatic cancer. We may be able to detect pancreatic cancer at its early stages by taking individuals’ saliva and looking at the ratios of these bacteria.”

In the USA, approximately 40,000 people die every year due to pancreatic adenocarcinoma, making it the fourth leading cause of cancer related death. The study was presented on May 18, 2014, at the Annual meeting of the American Society for Microbiology held May 17–20, 2014, in Boston (MA, USA).

Related Links:

San Diego State University 
Moores Cancer Center 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT

Channels

Molecular Diagnostics

view channel
Image: Unlike conventional molecular methods, VedaBio\'s CRISPR-based technology detects targets without requiring amplification (Photo courtesy of Veda Bio)

Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes

Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more